Holen Sie sich die Stockscreener-App
2.44
1.67%
0.04
Schlusskurs vom Vortag:
$2.40
Offen:
$2.35
24-Stunden-Volumen:
9,204
Relative Volume:
0.21
Marktkapitalisierung:
$20.68M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-12.47M
KGV:
-0.2749
EPS:
-8.877
Netto-Cashflow:
$-10.85M
1W Leistung:
+2.09%
1M Leistung:
-16.44%
6M Leistung:
-46.72%
1J Leistung:
+467.44%
1-Tages-Spanne:
$2.35
$2.49
1-Wochen-Bereich:
$2.18
$2.50
52-Wochen-Spanne:
$0.38
$6.7499
Neurobo Pharmaceuticals Inc Stock (NRBO) Company Profile
Firmenname
Neurobo Pharmaceuticals Inc
Sektor
Branche
Telefon
(857) 702-9600
Adresse
545 CONCORD AVENUE, CAMBRIDGE, MA
Vergleichen Sie NRBO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| NRBO | 2.40 | 20.68M | 0 | -12.47M | -10.85M | -8.877 |
| VRTX | 450.91 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 749.43 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.59 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.94 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.93 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Neurobo Pharmaceuticals Inc Stock (NRBO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-06-15 | Eingeleitet | H.C. Wainwright | Buy |
Neurobo Pharmaceuticals Inc Aktie (NRBO) Neueste Nachrichten
NeuroBo rebrands to MetaVia, changes Nasdaq ticker to MTVA By Investing.com - Investing.com Canada
NeuroBo Pharmaceuticals announces relignment, change name - TipRanks
NeuroBo rebrands to MetaVia, changes Nasdaq ticker to MTVA - Investing.com
NeuroBo Pharmaceuticals Rebrands Amidst Strategic Changes - TipRanks
Form 8-K NeuroBo Pharmaceuticals, For: Nov 15 - StreetInsider.com
NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaViaReflecting the Company's Focus on Cardiometabolic Diseases - Yahoo Finance
ARMISTICE CAPITAL, LLC Acquires Shares in NeuroBo Pharmaceuticals Inc - GuruFocus.com
NRBO: Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024 - Smartkarma
NeuroBo Pharmaceuticals to Participate in Investor Conferences in November - cnhinews.com
NRBO: Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024... - Yahoo Finance
NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update - citybiz
NRBO stock touches 52-week low at $2.55 amid market challenges - Investing.com
NeuroBo Pharmaceuticals Unveils Updated Corporate Presentation - TipRanks
Here's Why We're A Bit Worried About NeuroBo Pharmaceuticals' (NASDAQ:NRBO) Cash Burn Situation - Simply Wall St
NRBO stock touches 52-week low at $2.9 amid market challenges By Investing.com - Investing.com South Africa
NRBO stock touches 52-week low at $2.9 amid market challenges - Investing.com India
NRBO: Positive SAD Part 1 Data; MAD Part 2 Results Expected in 1Q25… - Zacks Small Cap Research
NeuroBo reports positive early trial results for obesity drug By Investing.com - Investing.com South Africa
NeuroBo reports positive early trial results for obesity drug - Investing.com
We're A Little Worried About NeuroBo Pharmaceuticals' (NASDAQ:NRBO) Cash Burn Rate - Yahoo Finance
NeuroBo’s DA-1726 Shows Promise in Obesity Trial Phase 1 - TipRanks
Affinity Asset Advisors LLC Invests $432,000 in NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) - Defense World
Nutkao, transaction in closing with Morocco's sovereign wealth fundEFA News - EFA News - European Food Agency
Berkley W R Corp Boosts Holdings in Nabors Energy Transition Corp. II (NASDAQ:NETD) - MarketBeat
Bank of Montreal Can Decreases Stock Position in Novo Nordisk A/S (NYSE:NVO) - Defense World
National Bank of Canada (OTCMKTS:NTIOF) Hits New 1-Year High at $94.20 - Defense World
70,000 Shares in Neurogene Inc. (NASDAQ:NGNE) Purchased by Integral Health Asset Management LLC - Defense World
NVO Stock Down on Unsatisfactory Data From Mid-Stage Obesity Study - Yahoo Finance
BMO maintains stock target on Novo Nordisk, cites trial results - Investing.com
Lombard Odier Asset Management Europe Ltd Reduces Stock Position in nVent Electric plc (NYSE:NVT) - Defense World
Avoro Capital Advisors LLC Makes New Investment in Neurogene Inc. (NASDAQ:NGNE) - Defense World
National Bank of Canada (OTCMKTS:NTIOF) Increases Dividend to $0.81 Per Share - MarketBeat
Amalgamated Bank Reduces Holdings in nVent Electric plc (NYSE:NVT) - Defense World
Dong-A ST executives sell NeuroBo Pharmaceuticals shares worth over $1,500 - Investing.com
BMO sustains stock target, outperform on Novo Nordisk amid trial results - Investing.com India
Novo Nordisk Sinks on Obesity Drug Study's Disappointing Results - Investopedia
What's Going On With NovaBay Pharmaceuticals Shares Friday? - Benzinga
Novo Nordisk Stock Declines After Headline Results From Mid-Stage Study Of Monlunabant In Obese Patients - Yahoo Finance
Novo Nordisk Shares Slide After Disappointing Obesity Pill Trial - Finimize
Novo Nordisk shares drop more than 4% on disappointing obesity pill data - The Economic Times
NVO Stock Loses Around $29B in 3 Months: Buy the Dip or Steer Clear? - Yahoo Finance
TD Cowen Reiterates Buy Rating on Novo Nordisk (NVO) Following Monlunabant Obesity Update - StreetInsider.com
Novo Nordisk shares drop nearly 5% on disappointing obesity pill data - Yahoo Finance
Novo Shares Fall on Safety Data for New Weight-Loss Drug - BNN Bloomberg
Novo drops to 1-month low after Monlunabant trial data - XM
NeuroBo shareholders approve significant stock issuance By Investing.com - Investing.com Australia
NeuroBo shareholders approve significant stock issuance - Investing.com India
Novo Nordisk: The Street Is Not Seeing The Growth Acceleration Potential (NYSE:NVO) - Seeking Alpha
NRBO: Data from Part 1 of Phase 1 Trial of DA-1726 in 3Q24… - Zacks Small Cap Research
NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update - citybiz
NeuroBo Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits - Quantisnow
Finanzdaten der Neurobo Pharmaceuticals Inc-Aktie (NRBO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):